![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
SM Florin, R Kuczenski and DS Segal
Psychiatry Department, School of Medicine, University of California, San Diego, La Jolla, USA.
Following reserpine pretreatment to disrupt vesicular stores of dopamine and norepinephrine, in vivo microdialysis was used in behaving rats to evaluate the role of vesicles in the neurochemical and behavioral responses to amphetamine and cocaine. Reserpine (2.5 mg/kg, 24 hr) completely prevented the hippocampus norepinephrine responses to 20 mg/kg of cocaine and to 0.5, 1.25 and 5.0 mg/kg of amphetamine. Likewise, reserpine almost completely abolished the caudate putamen dopamine response to cocaine. In contrast, the effect of reserpine on the amphetamine-induced dopamine response varied as a function of amphetamine dose. Although the dopamine response to 1.25 mg/kg of amphetamine was unchanged by reserpine pretreatment, the dopamine responses to both the lowest (0.5 mg/kg) and highest (5.0 mg/kg) doses of amphetamine were significantly attenuated by about 65% and 50%, respectively. These results indicate that the norepinephrine response to amphetamine is dependent on vesicular stores of transmitter at all doses of the drug. However, although amphetamine can release dopamine from a reserpine-resistant (non-vesicular) pool, it also appears that this response partially depends on vesicular stores, especially at low and high doses of drug. Concomitant behavioral assessments revealed that the behavioral responses to cocaine and the lowest dose of amphetamine, like the dopamine responses, were significantly suppressed by reserpine pretreatment. In contrast, at the intermediate dose of amphetamine, stereotypies were significantly enhanced. These altered behavioral profiles are discussed in terms of a balance between increases in both dopamine and norepinephrine produced by amphetamine.
This article has been cited by other articles:
|
|
 |
|
  E. Escubedo, C. Chipana, M. Perez-Sanchez, J. Camarasa, and D. Pubill Methyllycaconitine Prevents Methamphetamine-Induced Effects in Mouse Striatum: Involvement of {alpha}7 Nicotinic Receptors J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 658 - 667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. U. Adachi, M. Satomoto, H. Higuchi, K. Watanabe, S. Yamada, and T. Kazama Halothane enhances dopamine metabolism at presynaptic sites in a calcium-independent manner in rat striatum Br. J. Anaesth., October 1, 2005; 95(4): 485 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Bamford, S. Robinson, R. D. Palmiter, J. A. Joyce, C. Moore, and C. K. Meshul Dopamine Modulates Release from Corticostriatal Terminals J. Neurosci., October 27, 2004; 24(43): 9541 - 9552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Giorgetti, J. I. Javaid, J. M. Davis, E. Costa, A. Guidotti, S. B. Appel, and M. S. Brodie Imidazenil, a Positive Allosteric GABAA Receptor Modulator, Inhibits the Effects of Cocaine on Locomotor Activity and Extracellular Dopamine in the Nucleus Accumbens Shell Without Tolerance Liability J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 58 - 66. [Abstract] [Full Text]
|
|
|
|
|
|
D. S. Segal and R. Kuczenski An Escalating Dose "Binge" Model of Amphetamine Psychosis: Behavioral and Neurochemical Characteristics J. Neurosci., April 1, 1997; 17(7): 2551 - 2566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Hess, K. A. Collins, and M. C. Wilson Mouse Model of Hyperkinesis Implicates SNAP-25 in Behavioral Regulation J. Neurosci., May 1, 1996; 16(9): 3104 - 3111. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
